Taylor Frigon Capital Management’s Apyx Medical APYX Stock Holding History

Taylor Frigon Capital Management’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86M	Sell	413,602 -957	-0.2%	-$3.79K	0.87%	60
2026 Q1	$1.53M	Sell	414,559 -23,402	-5%	-$87.5K	0.87%	67
2025 Q4	$1.53M	Sell	437,961 -32,691	-7%	-$114K	0.78%	76
2025 Q3	$1.01M	Sell	470,652 -8,252	-2%	-$17.5K	0.5%	87
2025 Q2	$1.08M	Sell	478,904 -34,761	-7%	-$48.9K	0.57%	86
2025 Q1	$704K	Sell	513,665 -32,083	-6%	-$44.2K	0.42%	90
2024 Q4	$862K	Sell	545,748 -51,128	-9%	-$71.5K	0.44%	90
2024 Q3	$740K	Sell	596,876 -43,690	-7%	-$55.2K	0.37%	86
2024 Q2	$858K	Buy	640,566 +2,856	+0.4%	+$4.21K	0.41%	83
2024 Q1	$867K	Sell	637,710 -1,255	-0.2%	-$2.67K	0.41%	81
2023 Q4	$1.67M	Buy	638,965 +17,818	+3%	+$43.1K	0.84%	47
2023 Q3	$1.99M	Buy	621,147 +85,596	+16%	+$399K	1.1%	35
2023 Q2	$2.69M	Sell	535,551 -268,879	-33%	-$1.36M	1.32%	31
2023 Q1	$2.32M	Buy	804,430 +321,239	+66%	+$938K	1.27%	29
2022 Q4	$1.13M	Sell	483,191 -14,123	-3%	-$43.1K	0.64%	72
2022 Q3	$2.23M	Buy	497,314 +3,136	+0.6%	+$22.5K	1.16%	33
2022 Q2	$2.9M	Sell	494,178 -15,916	-3%	-$81.7K	1.51%	22
2022 Q1	$3.33M	Buy	510,094 +1,514	+0.3%	+$14.9K	1.24%	34
2021 Q4	$6.52M	Sell	508,580 -65,619	-11%	-$918K	2.04%	14
2021 Q3	$7.95M	Sell	574,199 -1,090	-0.2%	-$11.5K	2.56%	4
2021 Q2	$5.93M	Sell	575,289 -36,423	-6%	-$361K	1.85%	15
2021 Q1	$5.91M	Sell	611,712 -9,344	-2%	-$93.5K	1.82%	23
2020 Q4	$4.47M	Buy	621,056 +55,442	+10%	+$367K	1.47%	36
2020 Q3	$2.66M	Buy	565,614 +9,163	+2%	+$45.4K	1.17%	42
2020 Q2	$3.09M	Buy	556,451 +71,021	+15%	+$295K	1.53%	23
2020 Q1	$1.74M	Buy	485,430 +66,560	+16%	+$447K	1.37%	32
2019 Q4	$3.54M	Sell	418,870 -20,978	-5%	-$152K	2.44%	3
2019 Q3	$2.98M	Sell	439,848 -9,450	-2%	-$67.1K	2.15%	5
2019 Q2	$3.02M	Buy	449,298 +222,316	+98%	+$1.21M	2.1%	7
2019 Q1	$1.43M	Buy	+226,982	New	+$1.76M	1.11%	41

Other funds holding APYX

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SBCM

Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Taylor Frigon Capital Management's APYX Position: Q2 2026 in Review

Taylor Frigon Capital Management reduced its Apyx Medical (APYX) stake by 0.23% in Q2 2026, selling an estimated $3.79K and leaving 413,602 shares worth $1.86M. The position accounts for 0.87% of the portfolio, ranked #60.

Taylor Frigon Capital Management first reported a position in APYX in Q1 2019 and has held it in 30 quarters since. The position peaked at $7.95M in Q3 2021. 68 funds tracked by Wall St. Rank hold APYX as of Q2 2026.

Taylor Frigon Capital Management held 413,602 shares of Apyx Medical worth $1.86M as of Q2 2026.
Taylor Frigon Capital Management sold 957 Apyx Medical shares in Q2 2026, an estimated $3.79K.
Apyx Medical made up 0.87% of Taylor Frigon Capital Management's portfolio in Q2 2026, its #60 holding.
Taylor Frigon Capital Management first reported a position in Apyx Medical in Q1 2019 and has held it in 30 quarters since.
Taylor Frigon Capital Management's Apyx Medical position peaked at $7.95M in Q3 2021.
68 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.

Based on Taylor Frigon Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.